Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Hepatitis C

  Free Subscription

Articles published in Dig Dis Sci

Retrieve available abstracts of 75 articles:
HTML format

Single Articles

    March 2021
  1. LE E, Chee G, Kwan M, Cheung R, et al
    Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment.
    Dig Dis Sci. 2021 Mar 26. pii: 10.1007/s10620-021-06941.
    PubMed     Abstract available

    February 2021
  2. KANG N, Chung JW, Jang ES, Jeong SH, et al
    Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients.
    Dig Dis Sci. 2021 Feb 25. pii: 10.1007/s10620-020-06762.
    PubMed     Abstract available

  3. EVON DM, Kim HP, Edwards A, Carda-Auten J, et al
    "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C.
    Dig Dis Sci. 2021 Feb 2. pii: 10.1007/s10620-021-06829.
    PubMed     Abstract available

    September 2020
  4. PATEL YA, Yao J, Proeschold-Bell RJ, Niedzwiecki D, et al
    Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C.
    Dig Dis Sci. 2020 Sep 23. pii: 10.1007/s10620-020-06616.
    PubMed     Abstract available

    August 2020
  5. DENG LX, Mehta N
    Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.
    Dig Dis Sci. 2020 Aug 29. pii: 10.1007/s10620-020-06550.
    PubMed     Abstract available

  6. HYUN HK, Cho EJ, Park SY, Hong YM, et al
    Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.
    Dig Dis Sci. 2020 Aug 28. pii: 10.1007/s10620-020-06533.
    PubMed     Abstract available

    July 2020
  7. CHANG ML, Hu JH, Chen WT, Lin MS, et al
    Interactive Impacts from Hepatitis C Virus Infection and Mixed Cryoglobulinemia on Complement Levels.
    Dig Dis Sci. 2020 Jul 31. pii: 10.1007/s10620-020-06507.
    PubMed     Abstract available

  8. OHFUJI S, Matsuura T, Tamori A, Kubo S, et al
    Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan.
    Dig Dis Sci. 2020 Jul 27. pii: 10.1007/s10620-020-06475.
    PubMed     Abstract available

  9. BENHAMMOU JN, Moon AM, Pisegna JR, Su F, et al
    Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C.
    Dig Dis Sci. 2020 Jul 11. pii: 10.1007/s10620-020-06457.
    PubMed     Abstract available

    May 2020
  10. HUYNH T, Hu KQ
    Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data.
    Dig Dis Sci. 2020 May 13. pii: 10.1007/s10620-020-06286.
    PubMed     Abstract available

  11. YUEN MF, Liu SH, Seto WK, Mak LY, et al
    Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
    Dig Dis Sci. 2020 May 8. pii: 10.1007/s10620-020-06281.
    PubMed     Abstract available

    April 2020
  12. OUZAN D, Larrey D, Guyader D, Remy AJ, et al
    Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.
    Dig Dis Sci. 2020 Apr 18. pii: 10.1007/s10620-020-06234.
    PubMed     Abstract available

    February 2020
  13. WONG K, Podboy A, Lavezo J, Goel A, et al
    Dead Meat: Glecaprevir/Pibrentasvir-Induced Statin Myonecrosis.
    Dig Dis Sci. 2020;65:399-400.

    January 2020
  14. BENITEZ TM, Fernando SM, Amini C, Saab S, et al
    Geographically Focused Collocated Hepatitis C Screening and Treatment in Los Angeles's Skid Row.
    Dig Dis Sci. 2020 Jan 24. pii: 10.1007/s10620-020-06073.
    PubMed     Abstract available

  15. VAN BOEMMEL-WEGMANN S, Lo Re V 3rd, Park H
    Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection.
    Dig Dis Sci. 2020 Jan 14. pii: 10.1007/s10620-019-06037.
    PubMed     Abstract available

  16. ENOMOTO M, Kawada N
    The Moral of Hepatic Fibrosis: Don't Always Believe Noninvasive Fibrosis Measurements.
    Dig Dis Sci. 2020 Jan 1. pii: 10.1007/s10620-019-06035.

    November 2019
  17. CHEN Y, Ji H, Shao J, Jia Y, et al
    Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis.
    Dig Dis Sci. 2019 Nov 23. pii: 10.1007/s10620-019-05918.
    PubMed     Abstract available

  18. HSU PY, Hsu CT, Yeh ML, Huang CF, et al
    Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
    Dig Dis Sci. 2019 Nov 13. pii: 10.1007/s10620-019-05938.
    PubMed     Abstract available

  19. LIANG KH, Zhang P, Lin CL, Wang SC, et al
    Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients.
    Dig Dis Sci. 2019 Nov 2. pii: 10.1007/s10620-019-05915.
    PubMed     Abstract available

    October 2019
  20. HUANG R, Rao H, Yang M, Gao Y, et al
    Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
    Dig Dis Sci. 2019 Oct 25. pii: 10.1007/s10620-019-05886.
    PubMed     Abstract available

  21. ZHANG G, Patel K, Moghe A, Reid A, et al
    Provider Perceptions of Hepatitis C Treatment Adherence and Initiation.
    Dig Dis Sci. 2019 Oct 23. pii: 10.1007/s10620-019-05877.
    PubMed     Abstract available

  22. ZOU B, Yeo YH, Jeong D, Park H, et al
    A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
    Dig Dis Sci. 2019 Oct 9. pii: 10.1007/s10620-019-05869.
    PubMed     Abstract available

    September 2019
  23. WU SF, Tseng CW, Ho YC, Chen YC, et al
    Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients.
    Dig Dis Sci. 2019 Sep 26. pii: 10.1007/s10620-019-05850.
    PubMed     Abstract available

    August 2019
  24. SHERMAN KE, Abdel-Hameed EA, Ehman RL, Rouster SD, et al
    Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index.
    Dig Dis Sci. 2019 Aug 29. pii: 10.1007/s10620-019-05815.
    PubMed     Abstract available

  25. SAYINER M, Stepanova M, De Avila L, Golabi P, et al
    Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients.
    Dig Dis Sci. 2019 Aug 27. pii: 10.1007/s10620-019-05786.
    PubMed     Abstract available

  26. WALLACE MC, Sek K, Francis RJ, Samuelson S, et al
    Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.
    Dig Dis Sci. 2019 Aug 22. pii: 10.1007/s10620-019-05781.
    PubMed     Abstract available

  27. ALI RO, Moon MS, Townsend EC, Hill K, et al
    Exploring the Link Between Platelet Numbers and Vascular Homeostasis Across Early and Late Stages of Fibrosis in Hepatitis C.
    Dig Dis Sci. 2019 Aug 12. pii: 10.1007/s10620-019-05760.
    PubMed     Abstract available

    In DAA We Trust: Key Factors Essential to HCV Elimination.
    Dig Dis Sci. 2019 Aug 6. pii: 10.1007/s10620-019-05748.

    July 2019
  29. COSTENTIN CE, Sogni P, Falissard B, Barbare JC, et al
    Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.
    Dig Dis Sci. 2019 Jul 25. pii: 10.1007/s10620-019-05724.
    PubMed     Abstract available

    April 2019
  30. ZOU WY, Choi K, Kramer JR, Yu X, et al
    Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
    Dig Dis Sci. 2019 Apr 30. pii: 10.1007/s10620-019-05641.
    PubMed     Abstract available

  31. VOILS CI, King HA, Thorpe CT, Blalock DV, et al
    Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment.
    Dig Dis Sci. 2019 Apr 29. pii: 10.1007/s10620-019-05621.
    PubMed     Abstract available

    March 2019
  32. AHMAD J, Reddy KR, Tillmann HL, Hayashi PH, et al
    Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury.
    Dig Dis Sci. 2019 Mar 29. pii: 10.1007/s10620-019-05591.
    PubMed     Abstract available

  33. PATEL K, Zickmund SL, Jones H, Reid A, et al
    Determinants of Hepatitis C Treatment Adherence and Treatment Completion Among Veterans in the Direct Acting Antiviral Era.
    Dig Dis Sci. 2019 Mar 22. pii: 10.1007/s10620-019-05590.
    PubMed     Abstract available

  34. FELD JJ, Krassenburg LAP
    What Comes First: Treatment of Viral Hepatitis or Liver Cancer?
    Dig Dis Sci. 2019 Mar 14. pii: 10.1007/s10620-019-05518.
    PubMed     Abstract available

    February 2019
  35. WU T, Konyn PG, Cattaneo AW, Saab S, et al
    New Face of Hepatitis C.
    Dig Dis Sci. 2019 Feb 13. pii: 10.1007/s10620-019-05511.
    PubMed     Abstract available

    December 2018
  36. SHETTY A, Buch A, Saab S
    Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients.
    Dig Dis Sci. 2018 Dec 17. pii: 10.1007/s10620-018-5404.
    PubMed     Abstract available

  37. LIU Y, Wang W, Zou Z, Hu Z, et al
    Hepatitis C Virus Entry into Macrophages/Monocytes Mainly Depends on the Phagocytosis of Macrophages.
    Dig Dis Sci. 2018 Dec 10. pii: 10.1007/s10620-018-5401.
    PubMed     Abstract available

    November 2018
  38. DE MARIA C, Ghidotti I, Grillo F, Giannini EG, et al
    Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.
    Dig Dis Sci. 2018 Nov 1. pii: 10.1007/s10620-018-5356.

    October 2018
  39. KHALILI M, Wong RJ
    Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net.
    Dig Dis Sci. 2018 Oct 11. pii: 10.1007/s10620-018-5316.

    September 2018
  40. YANNY B, Saab S, Durazo F, Latt N, et al
    Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naive Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.
    Dig Dis Sci. 2018 Sep 27. pii: 10.1007/s10620-018-5283.
    PubMed     Abstract available

  41. SHERMAN KE, Rouster SD, Kang M, Umbleja T, et al
    PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals.
    Dig Dis Sci. 2018 Sep 14. pii: 10.1007/s10620-018-5278.
    PubMed     Abstract available

    August 2018
  42. MARSHALL MC, Herrera JL
    Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
    Dig Dis Sci. 2018 Aug 20. pii: 10.1007/s10620-018-5247.
    PubMed     Abstract available

  43. SIKAVI C, Najarian L, Saab S
    Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
    Dig Dis Sci. 2018 Aug 9. pii: 10.1007/s10620-018-5215.
    PubMed     Abstract available

  44. TRAN AN, Sachdev R, Fricker ZP, Leber M, et al
    Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital.
    Dig Dis Sci. 2018 Aug 4. pii: 10.1007/s10620-018-5231.
    PubMed     Abstract available

    July 2018
  45. STEWART RA, MacDonald BR, Chu TC, Moore JD, et al
    Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population.
    Dig Dis Sci. 2018 Jul 16. pii: 10.1007/s10620-018-5205.
    PubMed     Abstract available

    March 2018
    Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.
    Dig Dis Sci. 2018 Mar 17. pii: 10.1007/s10620-018-5014.

  47. ABDEL-MONEIM A, Aboud A, Abdel-Gabbar M, Zanaty M, et al
    Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
    Dig Dis Sci. 2018 Mar 15. pii: 10.1007/s10620-018-5005.
    PubMed     Abstract available

  48. HU KQ, Cui W
    Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection.
    Dig Dis Sci. 2018 Mar 8. pii: 10.1007/s10620-018-4968.
    PubMed     Abstract available

    February 2018
  49. TANEJA S, Duseja A, De A, Mehta M, et al
    Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
    Dig Dis Sci. 2018 Feb 26. pii: 10.1007/s10620-018-4979.
    PubMed     Abstract available

  50. MAIER MM, Zhou XH, Chapko M, Leipertz SL, et al
    Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
    Dig Dis Sci. 2018 Feb 16. pii: 10.1007/s10620-018-4956.
    PubMed     Abstract available

    January 2018
  51. BENBOW JH, Elam AD, Bossi KL, Massengill DL, et al
    Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study.
    Dig Dis Sci. 2018 Jan 12. pii: 10.1007/s10620-017-4860.
    PubMed     Abstract available

  52. ABDEL-HAMEED EA, Rouster SD, Boyce CL, Zhang X, et al
    Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients.
    Dig Dis Sci. 2018 Jan 12. pii: 10.1007/s10620-017-4895.
    PubMed     Abstract available

    December 2017
  53. HOVAIDA M, Torrazza-Perez E, McCarthy D
    Liver Function Tests "Gone Viral": Acute Hepatitis of Uncertain Cause.
    Dig Dis Sci. 2017 Dec 1. pii: 10.1007/s10620-017-4849.

    November 2017
  54. PRIVITERA G, Spadaro L, Marchisello S, Fede G, et al
    Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.
    Dig Dis Sci. 2017 Nov 25. pii: 10.1007/s10620-017-4862.
    PubMed     Abstract available

    October 2017
  55. BOSCARINO JA, Moorman AC, Rupp LB, Zhou Y, et al
    Comparison of ICD-9 Codes for Depression and Alcohol Misuse to Survey Instruments Suggests These Codes Should Be Used with Caution.
    Dig Dis Sci. 2017;62:2704-2712.
    PubMed     Abstract available

    September 2017
  56. XING J, Spradling PR, Moorman AC, Holmberg SD, et al
    A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C.
    Dig Dis Sci. 2017 Sep 30. doi: 10.1007/s10620-017-4762.
    PubMed     Abstract available

  57. PARIKH ND, Fu S, Rao H, Yang M, et al
    Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA.
    Dig Dis Sci. 2017 Sep 25. doi: 10.1007/s10620-017-4776.
    PubMed     Abstract available

  58. HOSSAIN N, Puchakayala B, Kanwar P, Verma S, et al
    Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics.
    Dig Dis Sci. 2017 Sep 14. doi: 10.1007/s10620-017-4754.
    PubMed     Abstract available

  59. CHAN J, Gogela N, Zheng H, Lammert S, et al
    Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment.
    Dig Dis Sci. 2017 Sep 8. doi: 10.1007/s10620-017-4749.
    PubMed     Abstract available

  60. IKEDA K, Kawamura Y, Kobayashi M, Kominami Y, et al
    Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Dig Dis Sci. 2017 Sep 7. doi: 10.1007/s10620-017-4739.
    PubMed     Abstract available

    August 2017
  61. YAYA I, Roux P, Marcellin F, Salmon-Ceron D, et al
    Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort).
    Dig Dis Sci. 2017 Aug 5. doi: 10.1007/s10620-017-4703.

    June 2017
  62. AFSARI A, Lee E, Shokrani B, Boortalary T, et al
    Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.
    Dig Dis Sci. 2017 Jun 13. doi: 10.1007/s10620-017-4626.
    PubMed     Abstract available

  63. WU E, Yang M, Rao H, Fu S, et al
    Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China.
    Dig Dis Sci. 2017 Jun 1. doi: 10.1007/s10620-017-4619.
    PubMed     Abstract available

    May 2017
  64. ROGAL SS, McCarthy R, Reid A, Rodriguez KL, et al
    Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence.
    Dig Dis Sci. 2017 May 18. doi: 10.1007/s10620-017-4608.
    PubMed     Abstract available

  65. LENCI I, Bosa A, Milana M, Baiocchi L, et al
    Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation.
    Dig Dis Sci. 2017 May 12. doi: 10.1007/s10620-017-4594.

    April 2017
  66. DEVER JB, Ducom JH, Ma A, Nguyen J, et al
    Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.
    Dig Dis Sci. 2017 Apr 4. doi: 10.1007/s10620-017-4548.
    PubMed     Abstract available

    February 2017
  67. AHN J, Liu B, Bhuket T, Wong RJ, et al
    Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation.
    Dig Dis Sci. 2017 Feb 6. doi: 10.1007/s10620-017-4469.
    PubMed     Abstract available

    January 2017
    India Needs Effective Surveillance to Control Hepatitis C.
    Dig Dis Sci. 2017 Jan 3. doi: 10.1007/s10620-016-4436.

  69. DELLA-GUARDIA B, Evangelista AS, Felga GE, Marins LV, et al
    Diagnostic Accuracy of Transient Elastography for Detecting Liver Fibrosis After Liver Trannsplantation: A Specific Cut-Off Value Is Really Needed?
    Dig Dis Sci. 2017;62:264-272.
    PubMed     Abstract available

    October 2016
  70. BECK KR, Kim N, Khalili M
    Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
    Dig Dis Sci. 2016.
    PubMed     Abstract available

    September 2016
  71. NATARAJAN Y, White DL, El-Serag HB, Ramsey D, et al
    Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
    Dig Dis Sci. 2016.
    PubMed     Abstract available

  72. HE QF, Zhang QF, Zhang DZ
    Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    Dig Dis Sci. 2016.
    PubMed     Abstract available

  73. FOX R
    Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers.
    Dig Dis Sci. 2016.

    May 2016
  74. CHAK EW, Sarkar S, Bowlus C
    Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis.
    Dig Dis Sci. 2016.
    PubMed     Abstract available

    April 2016
  75. PECTASIDES E, Miksad R, Pyatibrat S, Srivastava A, et al
    Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report and Review of the Literature.
    Dig Dis Sci. 2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.